Level of evidence and therapeutic evaluation: need for more thoughts
- 18 May 2004
- journal article
- review article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 18 (3) , 365-372
- https://doi.org/10.1111/j.1472-8206.2004.00240.x
Abstract
The practice of evidence‐based medicine requires a tool to assess and discriminate available data based on objective grounds, thus facilitating access to reliable information. The level of evidence, conceptually and practically embedded in scientific activity, allows comparing the results from multiple studies testing an identical hypothesis along the lines of at least two dimensions. The first dimension deals with the design of the study, i.e. the extent to which bias is avoided or managed, the second with the quality of incorporated data. A third dimension specific to therapeutic evaluation focuses on the clinical relevance of the tested hypothesis. The concern of the final user of the information is thus put to the fore. Indeed, a general practitioner will be interested in the benefit for its patients whereas the concern of a biologist might significantly diverge from the former matter. The bulk of existing scales of level of evidence concentrate on methodology. Some may include the second dimension but none embrace the three of them. Seldom considered are matters regarding reproducibility and procedure. This is all the more unfortunate as reproducibility is a cornerstone of scientific progress. Moreover, scales used for overviews fail to take into account the methodology designed to produce the synthesis. Inconsistent existing scales prevent the emergence of a generally agreed standard. Therefore, there is a need to further specify the concept of level of evidence in therapy evaluation and design scales encompassing the three above‐mentioned dimensions: methodology of experiment, quality of data, and clinical relevance of the primary criterion.Keywords
This publication has 25 references indexed in Scilit:
- Systematic reviews in health care: Assessing the quality of controlled clinical trialsBMJ, 2001
- Any casualties in the clash of randomised and observational evidence?BMJ, 2001
- Sifting the evidence---what's wrong with significance tests? Another comment on the role of statistical methodsBMJ, 2001
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Methodologic guidelines for systematic reviews of randomized control trials in health care from the potsdam consultation on meta-analysisJournal of Clinical Epidemiology, 1995
- Falsificationism and clinical trialsStatistics in Medicine, 1991
- Assessing the clinical effectiveness of preventive maneuvers: Analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations A report by the Canadian task force on the periodic health examinationJournal of Clinical Epidemiology, 1990
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findingsJournal of the American College of Cardiology, 1984
- A method for assessing the quality of a randomized control trialControlled Clinical Trials, 1981